54results about "Hybrid cell preparation" patented technology

The invention discloses a preparation method and application of a tetraploid saccharomyces cerevisiae strain, and belongs to the technical field of bioengineering. Comprising the following steps: (1) knocking out an HO gene of diploid yeast LFN524, separating haploids through spore production, and identifying mating types of candidate haploid strains to obtain haploid strains with opposite mating types of haploids; (2) respectively culturing haploid strains of different mating types, inducing fusion of the haploid strains, and screening successfully fused diploid strains; and (3) inducing the successfully fused diploid strain to fuse again to obtain the tetraploid saccharomyces cerevisiae strain. The nucleic acid content of the strains 8-3 and 8-4 disclosed by the invention is obviously higher than that of a diploid stock plant, and the nucleic acid content can respectively reach 0.118 g / g-DCW and 0.096 g / g-DCW, which are respectively increased by 63.89% and 33.33%.

Provided herein is a conditionally-replicating serotype 5 adenovirus or adenoviral vector expressing a mutant E1A protein under control of a promoter that is responsive to hypoxia and inflammation and one or more immune modulators under control of a tumor-specific promoter. The adenovirus or adenoviral vector also comprises serotype 3 fiber domain. Also provided is a method of inducing cytotoxicity in tumor cells using a composition containing the adenovirus or adenoviral vector.

A method of alignment and fusion of cells with an electrical field includes firing a first fluid dispenser of an electrofusion device until a first impedance sensor in a first microfluidic channel of the electrofusion device detects a presence of a first cell. The method includes firing a second fluid dispenser of the electrofusion device until a second impedance sensor in a second microfluidic channel of the electrofusion device detects a presence of a second cell. The method includes moving the first cell and the second cell into a merging chamber of the electrofusion device by firing a third fluid dispenser of the electrofusion device, in response to alignment of the first cell in the first microfluidic channel with the second cell in the second microfluidic channel. The method further includes fusing the first cell and the second cell in the merging chamber by creating an electrical field in the merging chamber.

The invention belongs to the technical field of edible mushroom biological breeding, and particularly discloses a Stropharia rugoso-annulata breeding method based on Tricholoma giganteum and Stropharia rugoso-annulata protoplast fusion, which comprises the following steps: respectively preparing Stropharia rugoso-annulata protoplast and Tricholoma giganteum protoplast; performing thermal inactivation on the stropharia rugoso-annulata protoplast, and performing ultraviolet inactivation on the tricholoma giganteum protoplast; mixing the two inactivated protoplasts, and adding an induction reagent for protoplast fusion; coating the fusion product on a regeneration culture medium for culturing to obtain a fusion strain; screening a target fusion strain through an antagonism test and a molecular marker technology; fruiting management is carried out, and a new high-temperature-resistant stropharia rugoso-annulata strain is screened out. By optimizing protoplast preparation and PEG fusion promotion conditions, the distant fusion efficiency is remarkably improved, and a novel stropharia rugoso-annulata strain which can normally fruit at the high temperature of 30 DEG C and is excellent in agronomic character and good in flavor is successfully obtained in combination with an efficient screening and identification system.

The present disclosure relates to a novel isolated binding protein including a N-terminal pro-brain natriuretic peptide (NT-proBNP) antigen binding domain, and athe preparation method therefor. The antigen-binding domain includes at least one complementarity determining region selected from the amino acid sequences as defined in the present disclosure: or; has at least 80% sequence identity with the complementarity determining region of the following amino acid sequence and has an affinity of KD≤2.26×10-8 to NT-proBNP. The binding protein may be used in the detection field of NT-proBNP protein.

This disclosure provides anti-5T4 antibodies, variants thereof and humanized versions. The newly disclosed antibodies exhibited high affinity to the 5T4 protein and can be used to treat cancers.

This disclosure provides, among other things, strategies for minimizing antibody diversification in a transgenic animal that uses gene conversion for antibody diversification. In some embodiments, the animal may comprise a genome comprising an endogenous immunoglobulin light chain locus comprising: (a) a functional immunoglobulin light chain gene comprising a nucleic acid encoding a light chain variable region; and (b) a plurality of pseudogenes that are operably linked to the functional immunoglobulin light chain gene and that donate, by gene conversion, nucleotide sequence to the nucleic acid encoding a light chain variable region, wherein the pseudogenes are upstream or downstream of the functional immunoglobulin light chain gene and encode the same amino acid sequence as the light chain variable region of the functional immunoglobulin light chain gene of (a). In other embodiments, the locus may have a tandem array of coding sequences for the light chain.

The invention belongs to the food industry, relates to a novel method for producing casein compositions by culturing transgenic microorganisms in the presence of whey, and limits the environmental impact.

The application belongs to the field of stem cell biology and relates to a culture method of a 3D nerve immune organoid containing microglia cells, which comprises the following steps: S1, inducing induced pluripotent stem cells in ectoderm direction and mesoderm direction respectively to obtain nerve-like embryoid bodies and yolk sac-like embryoid bodies; S2, culturing the nerve-like embryoid bodies to make them differentiate into nerves to obtain nerve ring structures, re-digesting the nerve ring structures to obtain nerve progenitor cell single cells, and culturing the yolk sac-like embryoid bodies to make them generate macrophage progenitor cells; and S3, fusing the nerve progenitor cell single cells and the macrophage progenitor cells and continuing to culture to form the 3D nerve immune organoid containing microglia cells. The brain-like organoid of the application can realize the following functions: exploring the control of microglia cells on the proportion of progenitor cells in the development stage, the change of phagocytosis, the control on the number of mature neurons, the influence on cell proliferation and apoptosis, and simultaneously accepting external stimulation and making corresponding functional stress changes.

Provided are compositions and methods for prophylaxis and / or therapy of a variety of cancers which express a Claudin 6 (CLDN6) antigen. Included are recombinant T cell receptors (TCRs), polynucleotides encoding them, expression vectors that include the polynucleotides, and cells into which the polynucleotides have been introduced to produce modified cells, including CD4+ T cells, CD8+ T cells, and progenitor cells, such as hematopoietic stem cells. The modified cells are capable of direct and indirect recognition of a cancer ell expressing a CLDN6 antigen by human leukocyte antigen (HLA) class I and II restricted binding of the TCR to the CLDN6 antigen expressed by the cancer cell, with or without presentation of the antigen by antigen presenting cells. Also included is a method for prophylaxis and / or therapy of cancer by administering modified cells that express a recombinant TCR that binds to CLDN6.

The present disclosure is related to compositions and methods comprising genetically modified Arthrospira platensis strains that express methanogen-killing lytic enzymes (methanolysins) to inhibit methane emission produced by enteric archaea.

Recombinant proteobacteria, including γ-proteobacteria, comprising a heterologous acyl-ACP desaturase and a heterologous acyl-ACP thioesterase, wherein the native dual 3-hydroxy acyl-ACP dehydratase / isomerase is deleted are provided herein. The recombinant proteobacteria produce non-native monounsaturated free fatty acids or derivatives thereof. Methods of producing non-native monounsaturated free fatty acids or derivatives thereof are also provided, in addition to cell cultures and fatty acid compositions produced by the recombinant proteobacteria. The recombinant proteobacteria may be used to produce insect pheromones or precursors thereof, and fragrances or precursors thereof.

To provide a fusion protein that can be used to modify mitochondria.SOLUTION: There is provided a fusion protein comprising a mitochondrial outer membrane anchoring peptide and a desired pharmacological protein, in order to prepare modified mitochondria with a foreign protein bound to the outer membrane of the mitochondria. There is also provided a fusion protein comprising an antibody or a fragment thereof and a mitochondrial outer membrane anchoring peptide.SELECTED DRAWING: None

The invention discloses an early-maturing flammulina velutipes variety and application thereof in flammulina velutipes breeding, and belongs to the technical field of flammulina velutipes molecular breeding. According to the invention, a new germplasm is created by using a CRISPR-Cas9 gene editing technology, and the fruiting phenotype of the strain is finally changed by changing a key gene by using the gene editing technology, so that a new variety 'Shangjin No.2' is created. The new variety at least has the following advantages: the yield is high; stipes are long, pilei are internally buckled and thick, and the appearance quality is good; the health-care food has the characteristics of high asparagine content, high glutamine content, high polysaccharide content and high cis-linoleic acid content, and is high in nutritional value; the method has the advantages of short growth period and prematurity. According to the invention, a domestic leading edible mushroom precise breeding technology platform is established, and the method has important strategic significance for improving the core competitiveness of the edible mushroom industry in China.

The invention discloses a hypsizigus marmoreus strain and application thereof, the classification name of the hypsizigus marmoreus strain is Hypsizigus marmoreus strain is Hypsizigus marmoreus strain, the hypsizigus marmoreus strain is preserved in China Center for Type Culture Collection on November 20, 2025, the preservation number is CCTCC NO: M 20252630, and the preservation address is Wuhan University, China. The strain is obtained through multi-spore hybridization breeding and has the excellent characters that pilei are round, smooth and free of spots, stipes are thick and strong, the content of flavor amino acid is rich, the growth cycle is short, the yield is high, nutrition is rich and the like, and the yield of a single-bag sporocarp reaches 637 g and is increased by 12.7% compared with that of a parent RZ-24; the number of sporocarps is large, each fruit body contains 156 sporocarps, excellent commodity characters and high-yield stability are shown, and the method is suitable for large-scale cultivation and application.

The invention pertains to the food industry and relates to new methods for producing casein compositions by culturing transgenic microorganisms in presence of lactoserum, and limiting the environmental impact.

A method of preparing a genome-edited cell, in which a nucleic acid contained in a donor nucleic acid is introduced into the genome of a fused cell during the meiosis process thereof, and a method of promoting hybridization in which two or more types of cells are caused to hybridize during the meiosis process of the fused two or more types of cells having different traits.

The invention belongs to the technical field of artificial cultivation of medicinal fungi, and particularly relates to a ganoderma lucidum spore powder cultivation method capable of enhancing body immunity, which comprises the following steps: new strain cultivation, intelligent cultivation room construction cultivation, sterile cut-log matrix composite cultivation, directional spore collection and activity retention treatment. According to the invention, a molecular marker-assisted selection technology is adopted, strains with high content of beta-glucan and triterpenoids are accurately screened out from a wild ganoderma lucidum resource library, key gene markers related to synthesis of immune active components are determined through gene sequencing, and excellent strains are fused by using a protoplast fusion technology to cultivate a new strain. Therefore, the strain with high immune active component yield is quickly obtained, and the quality of the ganoderma lucidum spore powder and the effect of enhancing immunity are guaranteed from the source; by building the intelligent cultivation room, the most suitable environmental condition is provided for the growth of the lucid ganoderma, so that the growth of the lucid ganoderma and the synthesis and accumulation of immunocompetence components are promoted.

The present disclosure relates to compositions and methods comprising a genetically modified strain of Arthrospira prastrata that expresses a methanogen killer lyase (methanolysin) to inhibit methane emissions produced by the Enterochaea. The present disclosure also relates to methods and compositions comprising a genetically modified strain of Arthrospira prastrata that expresses a methanogen killer lyase (methanolysin) to inhibit methane emissions produced by the Enterochaea.

Genetically engineered bacteria which express RNAs or proteins that produce or represent agriculturally useful compounds including fertilizers and plant nutrients upon increases in cell density when grown in plant growth media such as soil are disclosed. Also disclosed are genetically engineered bacteria where expression of RNAs or proteins that produce or represent agriculturally useful compounds including fertilizers and plant nutrients can be inhibited upon reaching increased cell densities when grown in a fermenter or bioreactor.

The present invention relates to a new CDH17 antibody, a bispecific antibody constructed on the basis thereof and specifically binding to CDH17 and EGFR, or a CDH17, EGFR and CD16A transpacific antibody, a pharmaceutical composition comprising same, a preparation method, and a use.

This invention relates to the field of genetic engineering technology, and more particularly to an engineered bacterium with high substrate utilization efficiency, its construction method, and its applications. The method includes overexpressing laccase and lignin peroxidase in two monokaryotic Ganoderma lucidum strains, respectively, and then hybridizing the two monokaryotic strains to form a new Ganoderma lucidum. Ganoderma lingzhi MKLGE253252, depositary institution: China General Microbiological Culture Collection Center; address: No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing; deposit date: March 11, 2026; accession number: CGMCC No. 42594. It synergistically enhances lignin degradation capacity, mycelial utilization efficiency, and growth capacity, and significantly improves the strength of mycelial fiber sheath. This invention fundamentally solves the problems of low lignin utilization efficiency, slow mycelial growth, and insufficient mycelial sheath strength in existing technologies, providing a completely new technical path for the production of bio-based leather.

This invention belongs to the field of organoid preparation technology, specifically relating to a vascularized organoid and its preparation method. Its beneficial effects are that, through subcutaneous transplantation in mice, it was found that the blood vessels of the resulting organoids can be perfused with blood flow; the cultured organoids can grow larger and differentiate into corresponding functional structures.

In one embodiment, a multi-domain therapeutic protein is provided, the multi-domain therapeutic protein comprising a TfR binding delivery domain fused to an acidic sphingomyelinase polypeptide; and nucleic acid constructs and compositions that allow insertion and / or expression of the multi-domain therapeutic protein coding sequence into a target genomic locus, such as an endogenous ALB locus. The multi-domain therapeutic proteins and nucleic acid constructs and compositions can be administered to cells, populations of cells, or subjects, the present invention relates to multi-domain therapeutic protein nucleic acids, and can be used in methods of integrating multi-domain therapeutic protein nucleic acids into target genomic loci, methods of expressing multi-domain therapeutic proteins in cells, methods of treating acidic sphingomyelinase deficiency in subjects, and methods of preventing or reducing signs or onset of symptoms of acidic sphingomyelinase deficiency in subjects.

Disclosed herein are modified strains for reducing degradation of recombinantly expressed products secreted from a host organism and methods of using the modified strains. In some embodiments, to attenuate a protease activity in Pichia pastoris, the genes encoding enzymes the degrade proteases are inactivated or mutated to reduce or eliminate activity. In preferred strains, the protease activity of proteases encoded by PAS_chr4_0584 (YPS1-1) and PAS_chr3_1157 (YPS1-2) (e.g., polypeptides comprising SEQ ID NO: 66 and 67) is attenuated.

MLX1034 is from Polaribacter sp. Q13, and has the amino acid sequence of the 1,3 / 1,4-xylanase MLX1034 is listed in SEQ ID NO.1; a nucleotide sequence of the gene is listed in SEQ ID NO.2; the 1,3 / 1,4-xylanase MLX1034 in the invention is capable of efficiently and specifically degrading 1,3 / 1,4-xylan and producing xylooligosaccharides with DP values above one; in addition, the physical and chemical properties of the 1,3 / 1,4-xylanase MLX1034 are stable enough to hydrolyze 1,3 / 1,4-xylan at room temperature; the 1,3 / 1,4-xylanase MLX1034 is suitable for the industrial production of red algal xylooligosaccharides at low energy costs.

The present disclosure is directed to methods of releasing and detecting biomarkers, and more particularly methods of releasing biomarkers using a tearing and steeping methodology, followed by detection of the released biomarkers.

The present disclosure provides polypeptides (e.g., IRED polypeptides), polynucleotides, expression vectors, and host cells comprising the same, methods of producing polypeptides (e.g., IRED polypeptides), and methods of catalyzing the reduction of an imine group.

Multidomain therapeutic proteins comprising a TfR-binding delivery domain fused to an acid sphingomyelinase polypeptide and nucleic acid constructs and compositions that allow insertion of a multidomain therapeutic protein coding sequence into a target genomic locus such as an endogenous ALB locus and / or expression of the multidomain therapeutic protein coding sequence are provided. The multidomain therapeutic proteins and nucleic acid constructs and compositions can be administered to cells, populations of cells, or subjects and can be used in methods of integration of a multidomain therapeutic protein nucleic acid into a target genomic locus, methods of expression of a multidomain therapeutic protein in a cell, methods of treating acid sphingomyelinase deficiency in a subject, and methods of preventing or reducing the onset of a sign or symptom of acid sphingomyelinase deficiency in a subject.